BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Surovatamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Surovatamig\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06137118-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280106
DTEND;VALUE=DATE:20280107
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT06137118)
DESCRIPTION:Surovatamig\, phase 1/2.\nStudy: AZD0486 as Monotherapy in B-ce
 ll Acute Lymphoblastic Leukaemia\nEstimated primary completion: 6 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0613711
 8
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526793-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280421
DTEND;VALUE=DATE:20280422
SUMMARY:Surovatamig: Phase 2 readout est. (NCT06526793)
DESCRIPTION:Surovatamig\, phase 2\, Follicular Lymphoma.\nStudy: Surovatami
 g (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) 
 B-cell NHL\nEstimated primary completion: 21 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06526793
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04594642-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:Surovatamig: Phase 1 readout est. (NCT04594642)
DESCRIPTION:Surovatamig\, phase 1\, Follicular Lymphoma.\nStudy: A Study of
  AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma\nEstimated primary c
 ompletion: 19 June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/surovatamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04594642
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201558-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:Surovatamig: Phase 1 readout est. (NCT07201558)
DESCRIPTION:Surovatamig\, phase 1\, Systemic Lupus Erythematosus.\nStudy: S
 tudy Evaluating Safety\, Tolerability\, PK/PD of Surovatamig in Adult RA o
 r SLE Participants\nEstimated primary completion: 27 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07201558
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123454-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT07123454)
DESCRIPTION:Surovatamig\, phase 1/2\, B-Cell Non-Hodgkin Lymphoma.\nStudy: 
 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticance
 r Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymph
 oma\nEstimated primary completion: 4 July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07123454
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571746-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Surovatamig: Phase 2 readout est. (NCT07571746)
DESCRIPTION:Surovatamig\, phase 2.\nStudy: A Study to Assess the Effect of 
 Surovatamig in Adult Participants With Antibody-mediated Kidney Disease\nE
 stimated primary completion: 13 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07571746
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564038-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300520
DTEND;VALUE=DATE:20300521
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT06564038)
DESCRIPTION:Surovatamig\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: A Stud
 y of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents f
 or Mature B-Cell Malignancies\nEstimated primary completion: 20 May 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06564038
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215585-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07215585)
DESCRIPTION:Surovatamig\, phase 3\, Large B-Cell Lymphoma.\nStudy: AZD0486 
 1L Therapy for Elderly or Unfit Participants With LBCL\nEstimated primary 
 completion: 10 June 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/surovatamig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07215585
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911553-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07911553)
DESCRIPTION:Surovatamig\, phase 3\, Large B-Cell Lymphoma.\nStudy: A Study 
 to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80
  Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Sco
 re 2 to 5\nEstimated primary completion: 2 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07911553
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509151-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20310829
DTEND;VALUE=DATE:20310830
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07509151)
DESCRIPTION:Surovatamig\, phase 3.\nStudy: Surovatamig as Consolidation The
 rapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocyt
 ic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)\nEst
 imated primary completion: 29 August 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07509151
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549595-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20311126
DTEND;VALUE=DATE:20311127
SUMMARY:Surovatamig: Phase 3 readout est. (NCT06549595)
DESCRIPTION:Surovatamig\, phase 3\, Follicular Lymphoma.\nStudy: A Study of
  Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular L
 ymphoma Patients\nEstimated primary completion: 26 November 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06549595
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736950-5561@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20350113
DTEND;VALUE=DATE:20350114
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07736950)
DESCRIPTION:Surovatamig\, phase 3\, Follicular Lymphoma.\nStudy: A Study Co
 mparing a New Drug (Surovatamig) With Standard Radiotherapy With or Withou
 t Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma\nEstima
 ted primary completion: 13 January 2035. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07736950
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
